Rigel (United States)

American biotechnology company in South San Francisco, California, founded in 1996 and listed on Nasdaq. Discovers, develops and commercialises small molecule medicines in haematology, oncology and immune disorders, with marketed products including fostamatinib for chronic immune thrombocytopenia, tavalisse and rezlidhia and gavreto in oncology, and a pipeline of kinase inhibitor programmes, supported by its own discovery research in signalling pathways.